Flex Pharma Reports Year End 2014 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Flex Pharm (FLKS) PT Raised to $27 at Cantor Fitzgerald Ahead of Consumer Product Launch
March 18, 2015 7:23 AM EDTCantor Fitzgerald analyst Mara Goldstein reiterated a Buy rating and raised her price target on Flex Pharma (NASDAQ: FLKS) to $27.00 (from $22.00) following Q4 results.
The price target hike reflect the pre-launch for the consumer product for exercise associated muscle cramps... More
